Stage IV Non-Small Cell Lung Cancer: Tomma's Patient Story
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Non-Small Cell Lung Cancer
- Spread to
- brain
- Treatment
- chemotherapy, radiation, targeted therapy and a clinical trial
- Outcome
- In Memory
Treatment course, step by step
- She joined a clinical trial that began with chemotherapy, followed by 7 weeks of radiation with chemotherapy, then several months of erlotinib.
- Three years later, a recurrence involving lymph nodes and the brain was treated with chemotherapy and radiation.
What happened, in summary
Tomma Hargraves discovered a small lump on the left side of her neck in 2006. A biopsy showed non-small cell lung cancer, and scans found a tumor in her right lung with extensive lymph node involvement. Her initial diagnosis was Stage III lung cancer.
Tomma chose to join a clinical trial testing an intensive treatment approach. She first received chemotherapy, then 7 weeks of radiation with additional chemotherapy, followed by several months of erlotinib. At the end of 9 months of treatment, her oncologist told her the cancer was gone. Three years later, however, the cancer returned in lymph nodes and the brain. Chemotherapy and radiation controlled the recurrence, and she did not need further cancer treatment afterward.
Tomma continued annual follow-up and lived with lasting lung damage from radiation, but she described herself as doing well. She became a volunteer patient lay navigator, using her experience to provide practical and emotional support to people newly diagnosed with lung cancer. Her advocacy emphasized the role of research and clinical trials in creating better treatment options. Tomma died on September 7, 2023, after many years of survivorship and patient advocacy.
Where this story comes from
This is a lay summary of an account first published by AACR. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer